A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Inclusion Criteria: * Confirmed diagnosis of melanoma, ovarian cancer, sarcoma, breast cancer or non-small cell lung cancer (NSCLC) * Unresectable, relapsed and/or metastatic cancer with minimal or low disease burden. Disease may or may not be measurable and should not be rapidly progressive. Inadequate response, relapse and/or unacceptable toxicity with one or more prior systemic, surgical, or radiation cancer therapies, except patients with NSCLC and breast cancer who must have experienced an inadequate response and/or unacceptable toxicity with two or more prior systemic, surgical, or radiation cancer therapies. * Cancer expresses NY-ESO-1 * ≥ 18 years of age * Life expectancy of ≥ 6 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * ECG without evidence of clinically significant arrhythmia or ischemia * Negative pregnancy test for females of childbearing potential Exclusion Criteria: * Pregnant or nursing * Vaccine or other therapy directed against NY-ESO-1 at any time in the past and any investigational therapy within three weeks prior to IDC-G305 dosing * Significant immunosuppression * Cancer chemotherapy, G-CSF or GM-CSF within three weeks prior to the first study treatment * Significant autoimmune disease * Myocardial infarction within six months of treatment, active cardiac ischemia or Grade III or IV heart failure * Inadequate hematology or chemistry profiles * History of other cancer within three years * Active, concurrent or recent infection, including tuberculosis, hepatitis B, hepatitis C or HIV * Uveal melanoma * Brain metastases considered unstable